- Featured Product
- KD/KO Validated
PTEN Polyklonaler Antikörper
PTEN Polyklonal Antikörper für FC, IHC, IP, WB, ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human, Maus, Ratte und mehr (1)
Anwendung
WB, IP, IHC, IF, FC, CoIP, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 22034-1-AP
Synonyme
Galerie der Validierungsdaten
Geprüfte Anwendungen
Erfolgreiche Detektion in WB | DU 145-Zellen, C6-Zellen, HEK-293T-Zellen, HeLa-Zellen, Jurkat-Zellen, LNCaP-Zellen, Maushodengewebe, Maus-Thymusgewebe, MCF-7-Zellen, NIH/3T3-Zellen, Rattenhodengewebe |
Erfolgreiche IP | DU 145-Zellen |
Erfolgreiche Detektion in IHC | humanes Mammakarzinomgewebe, humanes Hodengewebe, humanes Kolonkarzinomgewebe, humanes Prostatakarzinomgewebe, Maushirngewebe Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen. |
Erfolgreiche Detektion in FC | HeLa-Zellen |
Empfohlene Verdünnung
Anwendung | Verdünnung |
---|---|
Western Blot (WB) | WB : 1:2000-1:10000 |
Immunpräzipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
Immunhistochemie (IHC) | IHC : 1:500-1:2000 |
Durchflusszytometrie (FC) | FC : 0.20 ug per 10^6 cells in a 100 µl suspension |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, check data in validation data gallery |
Veröffentlichte Anwendungen
KD/KO | See 17 publications below |
WB | See 138 publications below |
IHC | See 29 publications below |
IF | See 14 publications below |
IP | See 6 publications below |
CoIP | See 2 publications below |
Produktinformation
22034-1-AP bindet in WB, IP, IHC, IF, FC, CoIP, ELISA PTEN und zeigt Reaktivität mit human, Maus, Ratten
Getestete Reaktivität | human, Maus, Ratte |
In Publikationen genannte Reaktivität | human, Maus, Ratte, Rind |
Wirt / Isotyp | Kaninchen / IgG |
Klonalität | Polyklonal |
Typ | Antikörper |
Immunogen | PTEN fusion protein Ag17274 |
Vollständiger Name | phosphatase and tensin homolog |
Berechnetes Molekulargewicht | 47 kDa |
Beobachtetes Molekulargewicht | 55 kDa, 68 kDa |
GenBank-Zugangsnummer | BC005821 |
Gene symbol | PTEN |
Gene ID (NCBI) | 5728 |
Konjugation | Unkonjugiert |
Form | Liquid |
Reinigungsmethode | Antigen-Affinitätsreinigung |
Lagerungspuffer | PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3. |
Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
Phosphatase and tensin homolog (PTEN) is an enzyme key in cell cycle regulation and in tumor suppression.
What is the molecular weight of PTEN?
PTEN is composed of 403 amino acid residues with an N-terminal domain with phosphatase activity and a
C-terminal C2 domain that binds phospholipid membranes (PMID:14749127). This antibody can recognize
two isoforms with MWs of 55kDa and 68 kDa.
What is the function of PTEN?
Widely expressed throughout the body, PTEN is found in the cytoplasm and inhibits cell cycle progression
through phosphatase activity. It regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate (PIP3)
by catalyzing the dephosphorylation of the inositol ring. This function counteracts the growth-stimulating
activity of the PI3K/AKT signaling pathway and thereby suppresses proliferation. Therefore, in homeostasis,
PTEN promotes chromosome stability and DNA repair (PMID: 24387334).Expression and function can be
regulated by posttranslational modifications, including acetylation for decreased catalytic activity and
ubiquitination for protein degradation, nuclear localization, and inhibition of phosphatase activity
(PMID: 24656806).
What is the role of PTEN in cancer?
PTEN was first identified as a tumor suppressor when mutations or deletions were identified by two separate
groups in a number of different cancer types including gliomas, breast, prostate, and kidney cancer
(PMID: 9090379; PMID: 9072974). Non-inherited, or somatic, mutations in PTEN that lead to a loss of function
in the protein have been shown to drive malignancy in tumors. PTEN hamartoma tumor syndrome (PHTS) is a
group of inherited disorders that occur as a result of autosomal dominant mutations in the PTEN gene. These
disorders include Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and Proteus syndrome. Because of
the constitutive expression of PTEN, the symptoms are varied but often include neurodevelopmental issues and
an increased risk of developing tumors, both benign and malignant (PMID: 26564076).
Protokolle
Produktspezifische Protokolle | |
---|---|
WB protocol for PTEN antibody 22034-1-AP | Protokoll herunterladen |
IHC protocol for PTEN antibody 22034-1-AP | Protokoll herunterladen |
IP protocol for PTEN antibody 22034-1-AP | Protokoll herunterladen |
Standard-Protokolle | |
---|---|
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
Species | Application | Title |
---|---|---|
Nat Commun Myo9b mutations are associated with altered dendritic cell functions and increased susceptibility to autoimmune diabetes onset | ||
Biomater Res High yield engineered nanovesicles from ADSC with enriched miR-21-5p promote angiogenesis in adipose tissue regeneration | ||
Drug Des Devel Ther Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (Lév.) Hutch Against IgA Nephropathy | ||
J Pineal Res Melatonin increases susceptibility to atrial fibrillation in obesity via Akt signaling impairment in response to lipid overload | ||
Theranostics Histone demethylase JMJD3 protects against renal fibrosis by suppressing TGFβ and Notch signaling and preserving PTEN expression. | ||
Cell Prolif YTHDC1 positively regulates PTEN expression and plays a critical role in cisplatin resistance of bladder cancer |